
FDA Approves Denosumab Biosimiliars for Prior Authorized Indications
The FDA approved denosumab-bmwo (CT-P41; Stoboclo) and denosumab-bmwo (CT-P41; Osenvelt) for indications previously approved for reference agents denosumab (Prolia) and denosumab (Xgeva), respectively, per an announcement from the developer, Celltrion.1 “ …